NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

Clinical trial NCT06651151 · RECRUITING

Trial details

NCT number: NCT06651151
Sponsor: Oslo University Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Stage IIIB-IV

Start date: 2024-11-01
Primary completion: 2026-05-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.